GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » PE Ratio (TTM)
中文

Pacific Biosciences of California (Pacific Biosciences of California) PE Ratio (TTM) : At Loss (As of Apr. 24, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-24), Pacific Biosciences of California's share price is $1.36. Pacific Biosciences of California's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.21. Therefore, Pacific Biosciences of California's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Pacific Biosciences of California's PE Ratio (TTM) or its related term are showing as below:

PACB' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 376.56   Max: 559.11
Current: At Loss


During the past 13 years, the highest PE Ratio (TTM) of Pacific Biosciences of California was 559.11. The lowest was 0.00. And the median was 376.56.


PACB's PE Ratio (TTM) is ranked worse than
100% of 407 companies
in the Medical Devices & Instruments industry
Industry Median: 27.17 vs PACB: At Loss

Pacific Biosciences of California's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.31. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.21.

As of today (2024-04-24), Pacific Biosciences of California's share price is $1.36. Pacific Biosciences of California's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.11. Therefore, Pacific Biosciences of California's PE Ratio without NRI for today is At Loss.

During the past 13 years, Pacific Biosciences of California's highest PE Ratio without NRI was 559.11. The lowest was 0.00. And the median was 376.56.

Pacific Biosciences of California's EPS without NRI for the three months ended in Dec. 2023 was $-0.27. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.11.

During the past 3 years, the average EPS without NRI Growth Rate was -23.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -12.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.50% per year.

During the past 13 years, Pacific Biosciences of California's highest 3-Year average EPS without NRI Growth Rate was 75.40% per year. The lowest was -162.90% per year. And the median was 9.70% per year.

Pacific Biosciences of California's EPS (Basic) for the three months ended in Dec. 2023 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.21.


Pacific Biosciences of California PE Ratio (TTM) Historical Data

The historical data trend for Pacific Biosciences of California's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California PE Ratio (TTM) Chart

Pacific Biosciences of California Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss 152.59 At Loss At Loss At Loss

Pacific Biosciences of California Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Pacific Biosciences of California's PE Ratio (TTM)

For the Medical Devices subindustry, Pacific Biosciences of California's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Biosciences of California's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's PE Ratio (TTM) falls into.



Pacific Biosciences of California PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Pacific Biosciences of California's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=1.36/-1.210
=At Loss

Pacific Biosciences of California's Share Price of today is $1.36.
Pacific Biosciences of California's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Pacific Biosciences of California  (NAS:PACB) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Pacific Biosciences of California PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Traded in Other Exchanges
Address
1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.
Executives
Oene Mark Van officer: Chief Operating Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline director 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim officer: Chief Financial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel officer: See Remarks 1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer officer: Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson director 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen officer: Chief Commercial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller director 400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer officer: VP Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez director 3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston director
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein director 1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025